Hikma Pharmaceuticals PLC (HIK) - Total Liabilities
Based on the latest financial reports, Hikma Pharmaceuticals PLC (HIK) has total liabilities worth GBX3.00 Billion GBX (≈ $365.38K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hikma Pharmaceuticals PLC - Total Liabilities Trend (2002–2024)
This chart illustrates how Hikma Pharmaceuticals PLC's total liabilities have evolved over time, based on quarterly financial data. See HIK working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Hikma Pharmaceuticals PLC Competitors by Total Liabilities
The table below lists competitors of Hikma Pharmaceuticals PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chia Ta World Co Ltd
TW:2033
|
Taiwan | NT$171.71 Million |
|
Global SM Tech Limited
KQ:900070
|
Korea | ₩35.90 Billion |
|
China Television Co
TW:9928
|
Taiwan | NT$3.11 Billion |
|
Hung Chou Fiber Ind Co Ltd
TW:1413
|
Taiwan | NT$1.50 Billion |
|
HILONG HOLDING LTD HD-10
F:8HL
|
Germany | €4.82 Billion |
|
Brand Group (M.G) Ltd
TA:BRND
|
Israel | ILA615.29 Million |
|
Acorn Energy, Inc. Common Stock
NASDAQ:ACFN
|
USA | $4.68 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down Hikma Pharmaceuticals PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HIK stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hikma Pharmaceuticals PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hikma Pharmaceuticals PLC (2002–2024)
The table below shows the annual total liabilities of Hikma Pharmaceuticals PLC from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX2.81 Billion ≈ $342.14K |
+13.80% |
| 2023-12-31 | GBX2.47 Billion ≈ $300.65K |
+6.37% |
| 2022-12-31 | GBX2.32 Billion ≈ $282.64K |
+21.94% |
| 2021-12-31 | GBX1.91 Billion ≈ $231.78K |
-4.13% |
| 2020-12-31 | GBX1.99 Billion ≈ $241.76K |
+10.33% |
| 2019-12-31 | GBX1.80 Billion ≈ $219.13K |
+0.06% |
| 2018-12-31 | GBX1.80 Billion ≈ $219.01K |
-3.23% |
| 2017-12-31 | GBX1.86 Billion ≈ $226.31K |
-4.71% |
| 2016-12-31 | GBX1.95 Billion ≈ $237.50K |
+56.79% |
| 2015-12-31 | GBX1.25 Billion ≈ $151.48K |
+20.29% |
| 2014-12-31 | GBX1.03 Billion ≈ $125.93K |
+15.64% |
| 2013-12-31 | GBX895.00 Million ≈ $108.90K |
+1.44% |
| 2012-12-31 | GBX882.26 Million ≈ $107.35K |
+13.55% |
| 2011-12-31 | GBX777.01 Million ≈ $94.54K |
+112.58% |
| 2010-12-31 | GBX365.52 Million ≈ $44.47K |
+7.68% |
| 2009-12-31 | GBX339.46 Million ≈ $41.30K |
-5.04% |
| 2008-12-31 | GBX357.46 Million ≈ $43.49K |
-23.84% |
| 2007-12-31 | GBX469.38 Million ≈ $57.11K |
+238.77% |
| 2006-12-31 | GBX138.56 Million ≈ $16.86K |
+25.41% |
| 2005-12-31 | GBX110.48 Million ≈ $13.44K |
+9.06% |
| 2004-12-31 | GBX101.31 Million ≈ $12.33K |
+76.52% |
| 2003-12-31 | GBX57.39 Million ≈ $6.98K |
+22.54% |
| 2002-12-31 | GBX46.84 Million ≈ $5.70K |
-- |
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more